The startup provides immune cell banking services utilizing its proprietary car-txpress platform to offer cost-effective storage solutions for immune cells. This service addresses the high costs associated with cell-based immunotherapy treatments, making them more accessible to clients.
Funding
Funding not disclosed
Founders
Product
Problem
Cell-based immunotherapy treatments, while promising, are often hindered by high costs associated with the collection, processing, and storage of immune cells. These costs can limit patient access to potentially life-saving therapies.
Solution
ImmuneCyte offers immune cell banking services designed to reduce the financial burden of cell-based immunotherapies. Utilizing its proprietary CAR-TXpress platform, ImmuneCyte provides cost-effective cryopreservation and storage solutions for a patient's or donor's immune cells. This allows for the preservation of immune cells at a point in time when they are healthy and functional, for potential use in future treatments. By lowering the costs associated with cell storage, ImmuneCyte aims to make these advanced therapies more accessible to a broader range of patients.
Target Audience
ImmuneCyte's primary customers include patients undergoing or considering cell-based immunotherapies, as well as researchers and pharmaceutical companies involved in cell therapy development.
Features
- Proprietary CAR-TXpress platform for efficient and cost-effective cryopreservation
- Long-term storage of immune cells, including T cells, NK cells, and other cell types
- Quality control and cell viability testing to ensure high-quality cell preservation
- Secure and compliant storage facilities with advanced monitoring systems